

## LABORATORY METHODS

# Generation and culture of osteoclasts

Silvia Marino<sup>1</sup>, John G Logan<sup>2</sup>, David Mellis<sup>3</sup> and Mattia Capulli<sup>4</sup>

<sup>1</sup>Academic Unit of Bone Biology, Department of Human Metabolism, Mellanby Centre for Bone Research, University of Sheffield, Sheffield, UK. <sup>2</sup>Department of Molecular Endocrinology, Imperial College London, Hammersmith Hospital, London, UK. <sup>3</sup>Musculoskeletal Research Programme, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK. <sup>4</sup>Department of Biotechnological and Applied Clinical Sciences, Bone Biopathology Laboratory University of L'Aquila, L'Aquila, Italy.

Osteoclasts are highly specialized cells of haematopoietic lineage that are uniquely responsible for bone resorption. In the past, osteoclasts were isolated as mature cells from chicken long bones, or were generated using osteoblasts or stromal cells to induce osteoclast formation in total bone marrow from mice or rabbits. The Copernican revolution in osteoclast biology began with the identification of macrophage-colony stimulating factor (M-CSF) and receptor activator NF $\kappa$ B-ligand (RANKL) as the key regulators of osteoclast formation, fusion and function. The availability of recombinant human and mouse M-CSF and RANKL has enabled researchers to reliably generate osteoclasts from primary monocyte/macrophage cells as well as from cell lines such as RAW 264.7. This article summarizes the most commonly used procedures for the isolation, generation and characterization of human, rodent and chicken osteoclasts *in vitro*. Lists of further reading and recommendations are included to facilitate a successful application by the reader.

BoneKEy Reports 3, Article number: 570 (2014) | doi:10.1038/bonekey.2014.65

### Introduction

Osteoclasts are one of the most distinct and specialized cell types found in the body. They are large, multinucleated, motile cells of haematopoietic lineage formed through the fusion of multiple monocyte or macrophage precursors.<sup>1</sup> Their survival, proliferation and differentiation from haematopoietic stem cells to functional osteoclasts is driven by two essential cytokines, macrophage-colony stimulating factor (M-CSF), secreted by osteoblasts, and receptor activator of NF $\kappa$ B ligand (RANKL), found as a soluble factor or as a membrane-bound cytokine expressed on osteoblasts, osteocytes, dendritic cells, mature T cells and haematopoietic precursors.<sup>2-7</sup>

The main function of osteoclasts is bone resorption: the degradation of both the hydroxyapatite mineral component of bone and the organic bone matrix. At the site of resorption, mature osteoclasts become polarized and attach to the bone surface through actin-rich podosomes. These form a circular structure, the actin ring, isolating the bone matrix from the

extracellular space in the 'sealing zone'. Within this 'zone' the complex folded membranes of the ruffled border serve as a secretory site for the protons, chloride ions and various enzymes required to degrade the organic and inorganic portions of the bone matrix.<sup>8,9</sup> Degraded resorption products are removed from the 'sealing zone' by endocytosis and transcytosis and are released from the basolateral membrane into the extracellular fluid away from the site of resorption.<sup>10</sup>

The ability to culture and study osteoclasts *in vitro* is therefore a key basic skill for any scientist wishing to study bone metabolism, the mechanisms of bone disease or any novel skeletal therapeutic agent.

In this technical review we have provided an overview of the different techniques used to generate, differentiate and analyse osteoclasts *in vitro*. This has been done by combining previously published protocols with those optimized in our laboratories, with the aim of giving a straightforward and comprehensive handbook.

Correspondence: Dr S Marino, Department of Human Metabolism, Academic Unit of Bone Biology, Mellanby Centre for Bone Research, University of Sheffield, D Floor Medical School, Room DU10 Beech Hill Road, Sheffield S10 2RX, UK.

E-mail: s.marino@sheffield.ac.uk

or Dr JG Logan, Department of Molecular Endocrinology, Imperial College London, Room 10N2B Commonwealth Building, Hammersmith Hospital, London W12 0NN, UK.

E-mail: J.Logan@Imperial.ac.uk

or Dr D Mellis, Institute of Medical Sciences, Foresterhill, Aberdeen AB25 2ZD, UK.

E-mail: d.mellis@abdn.ac.uk

or Dr M Capulli, Department of Biotechnological and Applied Clinical Sciences, Bone Biopathology Laboratory University of L'Aquila, Via Vetoio Coppito 2, L'Aquila 67100, Italy.

E-mail: mattiacapulli@gmail.com

Received 26 May 2014; accepted 8 July 2014; published online 10 September 2014

## Materials and Methods

### Historical osteoclast cultures

In the past, the only way to study osteoclasts *in vitro* was to extract them as mature cells from neonatal animals by fragmentation of their bones.<sup>11–14</sup> Subsequently, osteoclasts were generated by co-culturing osteoclast precursors with osteoblasts under osteoclastogenic conditions.<sup>15–17</sup> While the isolation of osteoclast precursors is still required for modern primary osteoclast *in vitro* techniques, in general these historical methods are now rarely used. However, for certain investigations these may still be the most appropriate culture to use and knowing them helps in understanding how modern methods were derived.

#### Isolation of mature osteoclasts

**Isolation of rabbit osteoclasts.** Mature rabbit osteoclasts can be isolated from the long bones (tibia and femur) of a 2–4-day-old rabbit. The limbs are carefully dissected out, the skin removed and the limbs transferred into a tube containing ice-cold phosphate-buffered saline (PBS). Using a scalpel/forceps, remove the soft tissues and articular cartilage and place the bones into fresh ice-cold PBS. In a Petri dish, finely mince all the isolated bones into small pieces in a small volume of culture medium that has not been supplemented with fetal calf serum (FCS). To do this, first cut the bones lengthwise, remove the marrow and then chop transversely as finely as possible. Avoid using FCS and perform this stage of the procedure as quickly as possible to prevent mature osteoclasts from adhering to the bottom of the dish. Transfer the medium containing the minced bones into a 50 ml conical tube and vigorously vortex for three 10-second bursts and then allow the bone fragments to settle for 3 min. Transfer the supernatant to a fresh centrifuge tube and add the required volume of culture medium supplemented with 10% FCS. Plate the cell suspension into Petri dishes and culture overnight under standard cell culture conditions. The next day remove the medium and gently wash the cell monolayer with sterile PBS to eliminate contaminating stromal and non-adherent cells. Add fresh culture medium and maintain under standard cell culture conditions<sup>18</sup> (**Figure 1a**).

**Isolation of chicken osteoclast.** Mature chicken osteoclasts can be isolated from female White Leghorn hens (*Gallus domesticus*) that have been kept for 7 days on a low-calcium diet.<sup>19</sup> The low-calcium diet enhances osteoclastogenesis and bone resorption, causing osteoclasts to not only cover the trabecular bone but also to be present in the bone marrow completely detached from the bone surface. It is interesting to note that chicken osteoclasts do not undergo apoptosis when detached from the bone and this is why this technique allows the isolation of mature osteoclasts.

After killing, femurs and tibias are collected, cleaned of soft tissue and placed in ice-cold PBS. The bones are then fragmented with sterile surgical blades and sharpened needles used to gently scrape the cells from the bone into fresh PBS. This suspension is transferred to a 15 ml tube and left to rest for a few minutes to allow the bone fragments to settle. When the fragments reach the bottom of the tube, the supernatant containing the cells is collected, transferred to a new 15 ml tube and centrifuged (250 *g* for 5 min). A fresh 15 ml tube is half filled with 10% albumin in PBS (or to increase cell viability PBS supplemented with 75% FBS) and the resuspended cells gently

layered on top. The tubes are left for 45 min to allow sedimentation of the cells by gravity. The supernatant is again collected and centrifuged (250 *g* for 5 minutes). The sedimentation/centrifugation cycle is repeated 3–4 times in order to obtain an enriched population of osteoclasts (90–95%). Resuspend the final cell pellet in culture medium and plate  $1 \times 10^5$  cells per 35 mm Petri dish. On average  $1–1.5 \times 10^6$  osteoclasts can be isolated from one chicken. After 24 h, replace half of the medium with fresh medium, and then after a further 24 h remove the medium gently and completely and replaced with fresh medium. On the third rinse the culture vigorously to remove non-adherent cells. The culture medium should be changed every other day<sup>20,21</sup> (**Figure 1b**).


**Isolation of rat osteoclasts.** Mature rat osteoclasts can be mechanically isolated from long bones of new-born rats (2–4 days). Long bones of new-born rats are isolated, cleared of soft tissues using sterile surgical blades and placed in ice-cold PBS. Bone cells are then isolated by finely chopping the bone using a scalpel blade, using osteoclast isolation medium buffered with HEPES.

The suspension and the small bone fragments are collected with a pipette and placed in a tube, where larger bone fragments are allowed to settle for 10 s. The cells are then dropped onto slices of devitalized bone, and placed onto plastic Petri dishes or glass coverslips according to the analysis needed. Osteoclasts are then allowed to seed and attach to the support (bone, plastic or glass) for 30 min, at 37 °C, at 5% CO<sub>2</sub>. The support is then washed in medium containing heat-inactivated fetal bovine serum (10% v/v) and placed in separate wells containing 2 ml of the same medium and cultured at 37 °C, 5% CO<sub>2</sub>, for up to 18 h.<sup>22</sup>


#### Isolation of osteoclast precursors

**Isolation of mouse osteoclast precursors.** To obtain osteoclast precursors from new-born mice, seven to nine 1-day-old mice are killed and placed in 90% alcohol. The hindlimbs and forelimbs are harvested and transferred into a sterile Petri dish on ice. Here, the soft tissues are carefully removed from the limbs with a sterile scalpel and the clean bones are placed in a new 35 mm Petri dish filled with 2 ml of culture medium that had been stored for 30 min in an incubator (5% CO<sub>2</sub>, 37 °C) to allow it to reach the correct pH and temperature. The bones are finely chopped using sterile surgical blades, and the bone marrow mechanically isolated from the bone fragments by pipetting the medium repeatedly using a sterile plastic Pasteur pipette. This step is repeated five times using fresh medium each time and the five fractions of bone marrow cells (containing both haematopoietic and stromal cells) are collected and combined in a 15 ml tube. The bone marrow cell suspension is centrifuged at 300 *g* for 3 min, the supernatant is discarded and the pellet is resuspended in 1 ml of culture medium<sup>23</sup> (**Figure 2a**).

To isolate adult mouse osteoclast precursors, total bone marrow is isolated from the long bones (tibia and femur) of 8–12-week-old mice. First, scissors are used to cut the hindlimbs from the dead mice while keeping the long bones intact. The paws and skin are removed from the limbs and placed in PBS for transport. The limbs are transferred to a sterile Petri dish and a scalpel is used to cut through the knee joint, separating the femur and the tibia. The remaining soft tissue is scraped from the bones and the epiphyses is cut off to expose the bone marrow. The culture medium is used to flush out the bone



**Figure 1** Schematic illustration of isolation of mature osteoclasts from 2–4-day-old rabbits (a) and white Leghorn hens (b). See text under Isolation of mature osteoclasts in Materials and methods section for more details.



**Figure 2** Schematic illustration of isolation of osteoclast precursors from new-born mice (a) and adult mice (b) peripheral blood (c). See text under Isolation of osteoclast precursors in Materials and methods section for more details.

marrow from each bone into a fresh sterile 60 mm Petri dish using a 5 ml syringe with a 25-gauge (G) needle. A single cell suspension is obtained by passing the flushed bone marrow through needles of decreasing size (19G→21→25G) and transferring it into a conical 15 ml tube. The cell suspension is then centrifuged at 300g for 3 min, the supernatant is discarded and the pellet is resuspended in 1 ml of culture medium (**Figure 2b**).

Isolation of human osteoclast precursors. To generate human osteoclasts, density centrifugation is used to isolate human peripheral blood mononuclear cells (PBMCs) from samples of

fresh peripheral/venous blood or from buffy coat. These samples must have been collected into anticoagulant vessels (e.g. EDTA or heparin coated). First, dilute 10 ml of the blood (or buffy coat) sample with 10 ml of warm, sterile PBS. Then take a conical 50 ml tube and pipet in 10 ml of Lymphoprep mixture (Ficoll-Paque may also be used and is equally potent for isolating PBMCs<sup>24</sup>). Slowly add the 20 ml of diluted blood sample onto the Lymphoprep using the side of the tube. The blood should form a layer on top of the Lymphoprep. Centrifuge the 50 ml tube at 800g for 30 min with the brake off. This will separate the solution into three layers, of which the small middle layer contains the PBMCs. Carefully collect this layer and

transfer it into a clean 50 ml tube. Add PBS until there is a total volume of 20 ml and resuspend the cells to wash them. Centrifuge the tubes at 300g for 3 min and discard the supernatant to remove any traces of Lymphoprep (additional washes may be done if necessary). Resuspend the cell pellet in culture medium (1 ml or more depending on the volume of the pellet) and estimate the cell number with a haemocytometer. The cells can be put straight into culture or aliquoted and stored in liquid nitrogen for use later<sup>25</sup> (**Figure 2c**).

**Osteoclast generating co-cultures.** Mouse osteoclasts can be generated from total bone marrow or by co-culturing previously isolated osteoblasts and bone marrow cells together. Both protocols use 1,25 Dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>) and prostaglandin E<sub>2</sub> (PGE<sub>2</sub>) to promote the expression of RANKL and M-CSF by osteoblasts, leading to osteoclast formation.

Total bone marrow is isolated as previously described and the cell suspension centrifuged at 300g for 3 min to collect the cells. Resuspend the pellet at a final concentration of  $2 \times 10^6$  cells ml<sup>-1</sup> in culture medium supplemented with  $10^{-8}$  M 1,25(OH)<sub>2</sub>D<sub>3</sub>. The medium should be changed the following day and every 3 days after that. The first osteoclasts will appear between 5 and 7 days after seeding and a good number should be present between days 7 and 10.

Using the method described above it is also possible to generate rabbit and human osteoclast-like cells using whole bone marrow isolated from 2–4 days-old rabbits or human adult volunteer donors respectively.

To generate osteoclasts using the bone marrow-osteoblast co-culture system, primary mouse calvarial osteoblasts are isolated from the calvarial bones of 2-day-old mice by sequential collagenase digestion.<sup>26</sup> Maintain the osteoblast culture under standard cell culture conditions until it reaches confluence (~3 days). Once confluent, treat the osteoblasts with trypsin for 3 min at 37 °C in order to detach the cells; then add culture medium and transfer the cells into a fresh 15 ml tube. Centrifuge at 300 g for 3 min, discard the supernatant and resuspend the osteoblast pellet in 1 ml of culture medium. Estimate osteoblast numbers using a haemocytometer and plate them into 96-well plates at  $8 \times 10^3$  cells per well in 150 µl of culture medium supplemented with 10 nM 1,25(OH)<sub>2</sub>D<sub>3</sub> and 1 µM PGE<sub>2</sub>. The next day (day 4), isolate the bone marrow cells as previously described. Remove 100 µl of culture medium from the 96-well plates and add the bone marrow cells at  $1.5\text{--}2 \times 10^5$  cells per well in 100 µl culture medium supplemented with 10 nM 1,25(OH)<sub>2</sub>D<sub>3</sub> and 1 µM PGE<sub>2</sub>. Incubate the culture under standard conditions and refresh the medium every other day until multinucleated osteoclasts are formed. The osteoblast layer can easily become detached if it is disturbed, and therefore care should be taken during medium changes. This can be advantageous at the end of the culture. The corner of the osteoblast layer can be detached by pipetting PBS onto the wall of the well, and the whole layer then removed by washing with further PBS. The purified osteoclasts will remain and can now be more easily analysed. The first osteoclasts will appear on day 7 or 8 and a large number should be present between days 9 and 11<sup>27</sup> (**Figure 3**).

### Current osteoclast culture methods

**M-CSF-RANKL-generated osteoclasts.** The generation and study of osteoclasts was forever changed by the identification of M-CSF


and RANKL as the essential cytokines responsible for the differentiation of haematopoietic stem cells into mature and functional osteoclasts.<sup>28–31</sup> M-CSF is secreted by osteoblasts and binds to the membrane receptor c-Fms expressed on early osteoclast precursors.<sup>31–33</sup> This interaction induces the expression of receptor activator of nuclear factor κB (RANK). RANKL is found as a soluble factor or as a membrane-bound cytokine expressed on osteoblasts, osteocytes, dendritic cells, mature T cells and haematopoietic precursors.<sup>34–37</sup> The binding of RANKL to RANK on the surface of osteoclast precursors initiates their differentiation, and fusion into osteoclasts, and enhances osteoclast survival and activity.<sup>38</sup>

Recombinant M-CSF and RANKL are now widely available, allowing researchers to easily generate large numbers of osteoclasts *in vitro* and study their formation and activity in the absence of other cell types.


A variety of cell populations can be driven to differentiate into multinucleated bone resorptive osteoclasts. This includes directly treating adult mouse bone marrow cells or mouse/human PBMCs with M-CSF (human or mouse 25–50 ng ml<sup>-1</sup>) and RANKL (human or mouse 10–120 ng ml<sup>-1</sup>). However, the number of osteoclast precursors present in these samples can be highly variable. It is therefore desirable to normalize the number of osteoclast precursors by using mouse/human M-CSF to expand the macrophage population prior to the addition of RANKL. Alternatively, the RAW 264.7 murine macrophage cell line<sup>38</sup> can be used as an abundant source of RANKL-sensitive osteoclast precursors. Regardless of the source of the precursors, a failure to generate osteoclasts is most often due to inactive M-CSF or RANKL. It is therefore recommended that every batch of cytokines be tested to determine the optimal concentration (dose–response curve) before any experimental cultures are undertaken. In addition, the serum used during a culture greatly affects the number of osteoclasts that will form. Several batches of FCS should be tested and the batch giving the best result reserved for osteoclast cultures.

**Osteoclast precursors.** Isolate the desired osteoclast precursors into a sterile 100 mm Petri dish and culture in medium supplemented with 25–50 ng ml<sup>-1</sup> of M-CSF. After 48–72 h the attached cells will be confluent M-CSF-dependent macrophages. Wash the monolayer with 5 ml ice-cold PBS and use a cell scraper to gently scrape the adherent M-CSF-dependent macrophages from the Petri dish. Collect the cells in culture medium and transfer them to a conical 15 ml tube. Centrifuge the tube at 300g for 3 min, discard the supernatant and resuspend the pellet in 1 ml of culture medium. Use a haemocytometer to estimate the number of M-CSF-dependent macrophages and then seed them in 96-well plates at  $12 \times 10^3$  cells per well in 150 µl culture medium supplemented with 25–50 ng ml<sup>-1</sup> M-CSF. Allow the M-CSF-dependent macrophages to attach overnight and then replace the medium with culture medium supplemented with M-CSF (25–50 ng ml<sup>-1</sup>) and RANKL (10–120 ng ml<sup>-1</sup>). Fifty per cent of this medium should be refreshed every 48 h. Osteoclasts will begin to form after 72–96 h (**Figure 4**).

RAW 264.7 cells. Rather than using primary cells, osteoclasts can be generated from some immortalized cell lines, of which the most commonly used is the murine macrophage cell line



**Figure 3** Timetable of bone marrow–osteoblast co-culture. See text under Osteoclast generating co-cultures in Materials and methods section for more details. This figure was adapted and modified from A.I. Idris unpublished data.




**Figure 4** Timetable of M-CSF/RANKL-generated osteoclasts. See text under M-CSF-RANKL-generated osteoclasts in Materials and methods section for more details. This figure was adapted and modified from A.I. Idris unpublished data.

RAW 264.7.<sup>39</sup> Using a cell line rather than primary cells confers several advantages, including wide availability, removing the need to cull a live animal, and ease of transfection. However, by their nature, cell lines may not react in the same way as primary cells and should be used only in preliminary studies or in parallel to primary investigations.

Cultures of RAW 264.7 cells can be maintained indefinitely in complete medium by scraping and sub-culturing the cells 1:3 whenever confluence is reached. To differentiate the cells into osteoclasts, cells are plated into 24-well plates at a concentration of  $1-4 \times 10^4$  cells in 500  $\mu$ l of complete medium supplemented with 20–100  $\text{ng ml}^{-1}$  RANKL. As RAW 264.7 cells express both M-CSF and its receptor c-fms, no treatment with M-CSF is necessary. On day 3 the medium should be replaced

with 500  $\mu$ l of fresh complete medium supplemented with 20–100  $\text{ng ml}^{-1}$  RANKL. Osteoclasts will first appear around day 4 and will be plentiful by day 5 or 6. The number of osteoclasts that form varies considerably with both the number of cells seeded and the passage number of the RAW 264.7 cells used. Early and late passages tend to produce low numbers of osteoclasts with optimal results achieved using cells from passages 4–18. RAW 264.7 cells can be grown and differentiated on plastic, glass or dentine depending on the experimental purpose and can be analysed using the same techniques as primary osteoclasts.

*Induced pluripotent stem cells.* Recently, Grigoriadis *et al.*<sup>40</sup> described an exciting new method for studying osteoclasts.



**Figure 5** TRACP-positive osteoclasts on dentin slices (a) and osteo assay surface multiple-well plates (b).

Using cocktails of growth factors and cytokines, they guided the differentiation of a reprogrammed human iPS cell line into osteoclasts. This method may possibly provide a reliable and renewable source of primary-like human osteoclasts and could allow the direct study of osteoclasts from patients with genetic disorders and the manipulation of these osteoclasts in novel genetic therapies.

Specialized embryonic cell culture techniques are required for this method and are best described in Grigoriadis *et al.*<sup>40</sup> In brief, the cells are differentiated over four stages: mesoderm induction, haematopoietic specification, haematopoietic expansion and maturation, and differentiation into osteoclasts. First, the formation of embryoid bodies with a mesoderm streak is induced by the treatment of 10–20 cell human iPS cell aggregates with BMP-4 and bFGF for 4 days in serum-free media. These embryoid bodies are then harvested and haematopoietic specification promoted by culturing with VEGF, bFGF, IL-6, IL-3, IL-11 and stem cell factor. On day 8 serum is added and treatment is changed to VEGF, EPO, TPO, IL-6, IL-3, IL-11 and stem cell factor. This promotes haematopoietic cell maturation and myeloid expansion. On days 18–22, the embryoid body is dissociated and the cells cultured on dentine in the presence of M-CSF and RANKL. Osteoclasts form after a further 10–14 days of culture and can be analysed using standard techniques.

### Characterization of osteoclast cultures

The following assays are commonly used to characterize osteoclasts.

**Staining for tartrate-resistant acid phosphatase.** Multinucleated osteoclasts are characterized by high expression of the enzyme tartrate-resistant acidic phosphatase as previously described in Coxon *et al.*,<sup>18</sup> and Itzstein and van't Hof.<sup>27</sup> This can easily be stained for and visualized. To do this, upon termination of an experiment, fix and stain the culture as follows:

Fixation:

1. Carefully rinse the culture with PBS (do not scratch the bottom of the well).
2. Fix cells with 4% formaldehyde in PBS for 10 min at room temperature.
3. Rinse twice with PBS and either stain immediately or store the plates at 4 °C.

**Staining:** Prepare the following solutions (see Supplemented materials). Greater detail of the components is given in supplementary materials:

*Solution A:*


- 150  $\mu$ l of Naphthol-AS-BI-phosphate solution
- 750  $\mu$ l of Veronal buffer
- 900  $\mu$ l of Acetate buffer
- 900  $\mu$ l of Acetate buffer with 100 nM Sodium Tartrate

*Solution B (do not mix vigorously):*


- 120  $\mu$ l of Pararosanilin
- 120  $\mu$ l of 4% Sodium Nitrate

Mix solutions A and B in a clean glass beaker and filter through a 0.45  $\mu$ m filter. Add 50–100  $\mu$ l per well (for a 96-well plate) of the filtered staining solution to the fixed cells and incubate at 37 °C. The time needed to obtain a good stain can vary between 30 and 60 min, and therefore the cells should be carefully monitored to avoid overstaining. When the desired level of stain has appeared, rinse with PBS and then add 200  $\mu$ l of 70% ethanol to each well. The plates should now be wrapped in cling film and stored at 4 °C. Tartrate-resistant acidic phosphatase-positive cells (bright red) containing 3 or more nuclei are osteoclasts (**Figure 5**). The number, size and number of nuclei of osteoclasts can be analysed by counting and image analysis. Alternatively, cells can be stained using a leucocyte acid phosphatase staining kit (Sigma 387A), or acid phosphatase activity can be directly measured with the acid phosphatase assay kit (Sigma CS0740).

**Detection of F-actin ring.** The formation of a ring of intracellular actin filaments in the sealing zone of an osteoclast is widely used as an indicator of correct polarization and resorptive activity. To study actin rings, osteoclasts can be grown on a glass slide or in an optic bottom flask, although for physiologically accurate rings osteoclasts should be grown on dentine. At the end of the culture, cells are fixed, permeabilized in 0.5% Triton X100 in PBS for 5 min at room temperature and then incubated with 0.5  $\mu$ g ml<sup>-1</sup> FITC- or TRITC-labelled Phalloidin for 30 min. The cells are then rinsed with PBS and F-actin rings can be visualized using fluorescence or confocal microscopy. High magnification can show the presence of



**Figure 6** F-actin ring generation (TRITC-labelled Phalloidin staining).



**Figure 7** Resorption pits on dentin slices (a), bone slice (b) and osteo assay surface multiple-well plates (c).

podosomes. These are highly specialized sub-cellular components, composed of actin microfilaments, actin-binding proteins, adhesion proteins, adapter proteins, signalling proteins, tyrosine kinases and integrin receptors. During osteoclast adhesion and polarization, podosomes will appear as randomly dispersed dots. They then cluster and move to the peripheral area of the cell where they form a podosome belt or actin ring (**Figure 6**). When the podosome belt is formed, osteoclasts can start the bone resorption process. The analysis of the actin ring can be very informative about the status of an osteoclast culture. The most common measure is the percentage of mature, multinucleated osteoclasts with a complete actin ring. This quantification provides the number of osteoclasts that have the morphological characteristic of a resorbing cell and should be always calculated when a deep characterization of an osteoclast culture is required.

**Resorption-pit assay.** The activity of multinucleated osteoclasts can be assessed using the resorption-pit assay. To activate the resorption process, a low pH is required as osteoclasts are 'activated' at a pH of  $\sim 6.9$ , whereas resorption is drastically reduced at pH above 7.2. Culture medium can be alkalinized with NaOH or acidified with concentrated HCl to allow resorption to occur in a controlled manner.<sup>41,42</sup> Mature osteoclasts, obtained using the methods described above, are removed from the dish using trypsin-EDTA solution. Cells are then plated on dentine or bone slices and allowed to resorb bone for 48 h. Pits can be analysed as follows:

(1) For dentine slices: Following tartrate-resistant acidic phosphatase staining, the surface of the slices are vigorously cleaned with tissue paper to remove the adherent cells. Resorption pits can then be visualized using a reflected light microscope as they will appear dark when

compared with the unresorbed areas. The resorbed area can be quantified using ImageJ or custom image analysis software.<sup>27</sup> The results are expressed as number of pits per osteoclast or area resorbed per osteoclast. It is important to normalize the resorbed pits/area by the number of osteoclasts to allow comparison between different cultures (**Figure 7a**).

(2) For bone slices: The slices are vigorously cleaned with a cotton swab to remove cells and then stained with 1% toluidine blue in order to reveal the resorbed areas. Resorption exposes collagen fibres in the bone and it is these that are toluidine blue stained. The pit area can be quantified using a number of software programs as above, or the Pit index can be computed. The Pit index was the first quantification method accepted for the analysis of pits.<sup>43</sup> In brief, the resorption pits are divided into three visual categories according to their diameter: small,  $< 10 \mu\text{m}$ ; medium,  $10\text{--}30 \mu\text{m}$ ; and large,  $> 30 \mu\text{m}$ . Each pit category is then given a score by multiplying the numbers of pits found by a different factor according to their dimensions: for small pits, 0.3; for medium pits, 1; and for large pits, 3. The sum of the three scores is the pit index. Osteoclast differentiation, morphology and viability can be studied using parallel bone slices (**Figure 7b**).

Osteoclast activity can also be directly detected by generating and culturing osteoclasts on osteo assay surface multiple-well plates. Following tartrate-resistant acidic phosphatase staining, the plates are incubated with a solution of 50% bleach for 10 min to remove the adherent osteoclasts. They are rinsed four times with PBS and then air-dried to visualize the surface properly. Resorption pits are visualized by light microscopy and the total area resorbed can be quantified using ImageJ software (**Figure 7c**).

## Materials

All reagents and materials used for collecting the samples, isolating the cells and culturing the cells should be sterile.

- Phosphate-buffered saline, pH 7.2 (PBS).
- Isolation and culture medium: minimal essential medium ( $\alpha$ MEM or DMEM) supplemented with 10% fetal calf serum (FCS), 5% L-Glutamine, 100 U ml<sup>-1</sup> penicillin and 100  $\mu$ g ml<sup>-1</sup> streptomycin (complete medium). A volume of 100 mM sodium Pyruvate and HEPES 1 M pH 7.2 can be added to the medium.
- Human/mouse recombinant RANKL at a working concentration of 10–120 ng ml<sup>-1</sup>.
- Human/mouse recombinant M-CSF at a working concentration of 25–50 ng ml<sup>-1</sup>.
- Lymphoprep or Ficoll-Paque.
- A 96-well plate, a 12-well plate or Petri dishes. Falcon tissue culture plate (produces the best results).
- Sterile scissors, tweezers, forceps and scalpels.
- Sterile syringes and needles (19, 21 and 25G).
- 4% Paraphormaldehyde.
- 1,25 Dihydroxyvitamin D<sub>3</sub> (1,25(OH)<sub>2</sub>D<sub>3</sub>).
- Prostaglandin E<sub>2</sub> (PGE<sub>2</sub>).
- Trypsin 1%.

## Supplemented materials

The stock solutions for TRAcP stain are prepared in glass containers as follows and kept at 4 °C.

- Veronal buffer: dissolve 1.17 g sodium acetate anhydrous and 2.94 g Veronal (Sodium 5,5-diethylbarbiturate) in 100 ml of distilled water.
- Acetate buffer: dissolve 0.82 g sodium acetate anhydrous in 100 ml of distilled water and adjusting the pH at 5.2 with glacial acetic acid.
- Pararosanilin solution: add 1 g of Pararosanilin powder to 20 ml of distilled water and add 5 ml of concentrated HCl. Carefully heat the solution to ~60 °C in water bath and stir until dissolved. Allow the solution to cool and filter.
- Naphthol-AS-BI-phosphate solution: Dissolve 10 mg ml<sup>-1</sup> of Naphthol-AS-BI-phosphate in Dimethylformamide. This solution should be prepared fresh before use, though it is stable at 4 °C for up to 2 weeks.

## Discussion

Obtaining a good osteoclast culture is an essential skill for a bone biologist, and is required for almost all high-level studies on bone physiology and pathology. Over the years many different protocols have been set up and tested, and hence it is now possible to select an appropriate protocol for any desired experiment or analysis.

We hope that this technical review will aid researchers in identifying the most appropriate protocol for their osteoclast studies. In fact, choosing the appropriate cellular model is essential to properly validate a hypothesis. For example, in a study investigating the effect of a drug treatment on osteoclasts, M-CSF and RANKL osteoclast cultures would be a good model for investigating direct effects on osteoclast formation. However, this culture would not account for any indirect effects of the treatment mediated by osteoblasts or stromal cells. If those were to be investigated, an osteoblast–osteoclast co-

culture could be used. This culture would then give information about the overall consequences to osteoclast formation, but would not differentiate between direct and indirect effects. Moreover, although both of these methods are useful for determining how a treatment moderates osteoclast formation, they would be less informative if an effect on osteoclast function needed to be determined. In this case, mature osteoclasts grown on dentine should be subjected to the treatment. These can be from M-CSF and RANKL cultures or co-cultures, but in some cases it may be most appropriate to directly isolate the mature cells using the techniques described in the historical section.

Recent findings have revealed new and unexpected roles for the bone and bone cells. These results show how bone interacts with other areas of study, including the immune, endocrine and reproductive systems, and bring scientists from these disciplines into the bone field. We hope that this protocol outline will help new and old bone students shed light into the functions of osteoclasts.

## Recommended Further Reading

### Bone Research Protocols:

Orriss IR and Arnett TR. Rodent osteoclast cultures. *Methods Mol Biol* 2012;**816**:103–117.

Collin-Osdoby P and Osdoby P. Isolation and culture of primary chicken osteoclasts. *Methods Mol Biol* 2012;**816**: 119–143.

Coxon FP, Rogers MJ and Crockett JC. Isolation and purification of rabbit osteoclasts. *Methods Mol Biol* 2012;**816**:145–158.

Henriksen K, Karsdal MA, Taylor A, Tosh D and Coxon FP. Generation of human osteoclasts from peripheral blood. *Methods Mol Biol* 2012;**816**:159–175.

Itzstein C and van 't Hof RJ. Osteoclast formation in mouse co-cultures. *Methods Mol Biol* 2012;**816**:177–186.

Collin-Osdoby P and Osdoby P. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. *Methods Mol Biol* 2012;**816**:187–202

Cody JJ, Rivera AA, Liu J, Liu JM, Douglas JT and Feng X. A simplified method for the generation of human osteoclasts *in vitro*. *Int J Biochem Mol Biol* 2011;**2**:183–189.

Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH *et al*. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. *Blood* 2010;**115**:2769–2776.

## Acknowledgements

Supported by the IBMS-ECTS Young Investigators. We gratefully acknowledge Dr Aymen I Idris and Professor Anna Teti for their valuable advice and support.

## Conflict of Interest

The authors declare no conflict of interest.

## References

1. Rosen CJ. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. 8th edn. Wiley-Blackwell: Ames, USA, 2013.
2. Jones DH, Kong YY, Penninger JM. Role of RANKL and RANK in bone loss and arthritis. *Ann Rheum Dis* 2002;**61**(Suppl 2):ii32–ii39.



3. Vaananen HK, Laitala-Leinonen T. Osteoclast lineage and function. *Arch Biochem Biophys* 2008;**473**:132–138.
4. Boyce BF, Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. *Arch Biochem Biophys* 2008;**473**:139–146.
5. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. *Nature* 2003;**423**:337–342.
6. Weir EC, Horowitz MC, Baron R, Centrella M, Kacinski BM, Insogna KL. Macrophage colony-stimulating factor release and receptor expression in bone cells. *J Bone Miner Res* 1993;**8**:1507–1518.
7. Ross FP. M-CSF, c-Fms, and signaling in osteoclasts and their precursors. *Ann N Y Acad Sci* 2006;**1068**:110–116.
8. Favus MJ. *Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. 5th edn. The American Society for Bone and Mineral Research: Washington, DC, USA, 2006.
9. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. *J Cell Biochem* 2007;**102**:1130–1139.
10. Salo J, Lehenkari P, Mulari M, Metsikko K, Vaananen HK. Removal of osteoclast bone resorption products by transcytosis. *Science* 1997;**276**:270–273.
11. Boyde A, Ali NN, Jones SJ. Resorption of dentine by isolated osteoclasts in vitro. *Br Dent J* 1984;**156**:216–220.
12. Chambers TJ, Revell PA, Fuller K, Athanasou NA. Resorption of bone by isolated rabbit osteoclasts. *J Cell Sci* 1984;**66**:383–388.
13. Arnett TR, Dempster DW. Effect of pH on bone resorption by rat osteoclasts in vitro. *Endocrinology* 1986;**119**:119–124.
14. Arnett TR, Dempster DW. A comparative study of disaggregated chick and rat osteoclasts in vitro: effects of calcitonin and prostaglandins. *Endocrinology* 1987;**120**:602–608.
15. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM *et al*. Osteoblastic cells are involved in osteoclast formation. *Endocrinology* 1988;**123**:2600–2602.
16. Takahashi N, Yamana H, Yoshiki S, Roodman GD, Mundy GR, Jones SJ *et al*. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. *Endocrinology* 1988;**122**:1373–1382.
17. Suda T, Takahashi N, Martin TJ. Modulation of osteoclast differentiation. *Endocr Rev* 1992;**13**:66–80.
18. Coxon FP, Rogers MJ, Crockett JC. Isolation and purification of rabbit osteoclasts. *Methods Mol Biol* 2012;**816**:145–158.
19. Zamboni ZA, Teti A, Pace G, Covelli V. Quantitative evaluation of experimentally induced osteocytic osteoplasia in hen's femur. *Boll Soc Ital Biol Sper* 1980;**56**:1038–1044.
20. Zamboni ZA, Teti A, Primavera MV. Isolated osteoclasts in primary culture: first observations on structure and survival in culture media. *Anat Embryol (Berl)* 1982;**165**:405–413.
21. Collin-Osdoby P, Osdoby P. Isolation and culture of primary chicken osteoclasts. *Methods Mol Biol* 2012;**816**:119–143.
22. Chambers TJ, Magnus CJ. Calcitonin alters behaviour of isolated osteoclasts. *J Pathol* 1982;**136**:27–39.
23. Rucci N, Rufo A, Alamanou M, Capulli M, Del FA, Ahman E *et al*. The glycosaminoglycan-binding domain of PRELP acts as a cell type-specific NF-kappaB inhibitor that impairs osteoclastogenesis. *J Cell Biol* 2009;**187**:669–683.
24. Yeo C, Saunders N, Locca D, Flett A, Preston M, Brookman P *et al*. Ficoll-Paque versus Lymphoprep: a comparative study of two density gradient media for therapeutic bone marrow mononuclear cell preparations. *Regen Med* 2009;**4**:689–696.
25. Henriksen K, Karsdal MA, Taylor A, Tosh D, Coxon FP. Generation of human osteoclasts from peripheral blood. *Methods Mol Biol* 2012;**816**:159–175.
26. Bakker AD, Klein-Nulend J. Osteoblast isolation from murine calvaria and long bones. *Methods Mol Biol* 2012;**816**:19–29.
27. Itzstein C, Van 't Hof RJ. Osteoclast formation in mouse co-cultures. *Methods Mol Biol* 2012;**816**:177–186.
28. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. *Biochem Biophys Res Commun* 1999;**256**:449–455.
29. Yasuda H, Shima N, Nakagawa N, Yamaguchi K, Kinoshita M, Mochizuki S *et al*. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998;**95**:3597–3602.
30. Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T *et al*. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. *Cell* 1998;**93**:165–176.
31. Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H *et al*. The murine mutation osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. *Nature* 1990;**345**:442–444.
32. Wiktor-Jedrzejczak W, Bartocci A, Ferrante Jr AW, Ahmed-Ansari A, Sell KW, Pollard JW *et al*. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. *Proc Natl Acad Sci USA* 1990;**87**:4828–4832.
33. Fuller K, Owens JM, Jagger CJ, Wilson A, Moss R, Chambers TJ. Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. *J Exp Med* 1993;**178**:1733–1744.
34. Ikeda T, Kasai M, Utsuyama M, Hirokawa K. Determination of three isoforms of the receptor activator of nuclear factor-kappaB ligand and their differential expression in bone and thymus. *Endocrinology* 2001;**142**:1419–1426.
35. Anderson DM, Maraskovsky E, Billingsley WL, Dougall WC, Tometsko ME, Roux ER *et al*. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. *Nature* 1997;**390**:175–179.
36. Nakashima T, Hayashi M, Fukunaga T, Kurata K, Oh-Hora M, Feng JQ *et al*. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. *Nat Med* 2011;**17**:1231–1234.
37. Wong BR, Josien R, Lee SY, Sauter B, Li HL, Steinman RM *et al*. TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor. *J Exp Med* 1997;**186**:2075–2080.
38. Teitelbaum SL. Bone resorption by osteoclasts. *Science* 2000;**289**:1504–1508.
39. Collin-Osdoby P, Osdoby P. RANKL-mediated osteoclast formation from murine RAW 264.7 cells. *Methods Mol Biol* 2012;**816**:187–202.
40. Grigoriadis AE, Kennedy M, Bozec A, Brunton F, Stenbeck G, Park IH *et al*. Directed differentiation of hematopoietic precursors and functional osteoclasts from human ES and iPS cells. *Blood* 2010;**115**:2769–2776.
41. Arnett TR. Extracellular pH regulates bone cell function. *J Nutr* 2008;**138**:415S–418SS.
42. Meghji S, Morrison MS, Henderson B, Arnett TR. pH dependence of bone resorption: mouse calvarial osteoclasts are activated by acidosis. *Am J Physiol Endocrinol Metab* 2001;**280**:E112–E119.
43. Caselli G, Mantovanini M, Gandolfi CA, Allegretti M, Fiorentino S, Pellegrini L *et al*. Tartronates: a new generation of drugs affecting bone metabolism. *J Bone Miner Res* 1997;**12**:972–981.